Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of pulmonology and hepatology drug developer InterMune
So what: The former Rule Breaker just published new results from long-term safety tests of Esbriet, a medicine for patients with mild to moderate idiopathic pulmonary fibrosis. As it turns out, the drug appears safe for extended treatment and perhaps ready for approval in the U.S. market.
Now what: IPF is an oftentimes fatal lung disease with a lower five-year survival rate than many cancers and more than 30,000 new cases discovered in just Europe every year. Esbriet was recently launched in Germany at an annual cost of $51,000 to the patient, and should enter a 100,000-patient test in America soon. Do the math and you'll see a potential multibillion-dollar blockbuster that could be to InterMune what Tysabri is to Elan
Interested in more information about InterMune? Add it to My Watchlist.
Fool contributor Anders Bylund holds no position in any of the companies discussed here. Motley Fool newsletter services have recommended buying shares of Elan and Pfizer. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. You can check out Anders' holdings and a concise bio, follow him on Twitter or Google+, or peruse our Foolish disclosure policy.